All In Biotech

Drug Trial Radar · NCT05636306

A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults

A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Nov 22, 2022

Primary completion

Oct 5, 2023

Study completion Oct 5, 2023

Sponsor

Lead sponsor
NoNO Inc.Industry
Sponsor type
Industry
First posted
Dec 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults. Participants will be administered a single intravenous dose of NoNO-42 or placebo. Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28.

Conditions

  • First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke

Interventions

  • NoNO-42Drug

    A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute

  • PlaceboDrug

    A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of AEs, abnormal laboratory findings and abnormal vital signsTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Company Inc.

    Mount Royal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.